Week of April 8-14 - Smart Woman Securities

footlickertreeBiotechnology

Dec 3, 2012 (4 years and 10 months ago)

183 views








Drug Manufacturers & Big Pharmaceuticals

Abbott Laboratories (ABT)



Abbott Laboratories is suing India’s Ranbaxy Laboratories in addition to Israel
-
based Teva
Pharmaceuticals and Sandoz of the Novartis group for allegedly violating Abbott’s patent
pr
otecting Omnicef, a drug used to treat ear, throat and skin infections. All three companies
currently being sued by Abbott had filed for permission to market their generic versions
ofOmnicef, arguing that the patent protecting the drug until 2011 is inval
id.


Merck & Co. (MRK)



Merck & Co surged 8.3% on Friday to close at $50.21, up $3.85, after a judge dismissed a class
-
action lawsuit that investors filed against the company. The stock’s price is the highest since
October 2003. The judge dismissed the
Vioxx suite because it was submitted too late under the
statute of limitations. The attorneys for the shareholders announced that they would be
repealing the ruling, an announcement that had little effect on the stock’s performance for the
rest of the
day
. Earlier in the week Merck announced its first quarter earnings for 2007, which
exceeded analyst expectations.



An FDA
advisory committee
voted 20
-
1 against approving Merck’s Arcoxia, which the
company had hoped to be Vioxx’s successor.
One member of th
e panel stated that there were
c
oncerns about the "overall cardiovascular safety of the drug" and with all drugs in the Cox
-
2
inhibitor class.


Pfizer Inc.
(
PFE
)




On

Wednesday distributor MWI Veterinary Supply Inc. announced that it reached a
distribution
agreement with Pfizer Inc. The products involved in the agreement include
livestock and equine products along with Rimadyl, an anti
-
inflammatory for dogs, and
Clavamox, an antibiotic for canines. The agreements extend until December 31, 2008. Stocks
of b
oth companies rose following the announcement, as Pfizer has continued to inch towards
recovery.


Biotechnology

Gilead Sciences (GILD)




A new study recently concluded that the market for AIDS medicine will reach $10.6 billion by
the year 2015. The report

did cite that drug makers like Gilead will be under pressure to
provide lower
-
cost HIV and AIDS medicines to the developing world; however, it predicts that
it will remain a fast
-
growing business in the West. The current market for AIDS treatments is
est
imated to be $7.1 billion. Gilead’s compound is considered to be one of the most promising
compounds in clinical trials (Phase II), along with Merck’s raltegravir (Phase III), because both
Healthcare Update
April 8
-
14

are integrase inhibitors. Gilead’s stock rose nearly $2 after the
report was publicized on
Thursday.


Medical Instruments & Supplies

Medtronic Inc. (MDT)



On Wednesday, Medtronic announced that it is combining its existing vascular and cardiac
surgery businesses to form Medtronic CardioVascular. The division includes 4
major units:
coronary and peripheral, endovascular innovations, structural heart disease, and
revascularization and surgical therapies. The new unit is expected to have combined revenues
of approximately $1.9 billion in the coming fiscal year.

Sources Ci
ted

www.wsj.com


http://biz.yahoo.com/rb/070412/aids_drugs.html?.v=3


http://www.zeenews.com/znnew/articles.asp?rep=2&aid=365563&ssid=53&sid=BUS


http://money.cnn.com/2007/04/12/news/companies/merck/index.htm?source=y
ahoo_quote


http://www.marketwatch.com/News/Story/Story.aspx?guid=%7b39C3A50D
-
5170
-
4606
-
B24A
-
8558A899F60A%7d&siteid=yhoo
&dist=yhoo